Zim Laboratories

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE518E01015
NSEID: ZIMLAB
BSEID: 541400
View on NSE | View on BSE

INR

88.02

3.32 (3.92%)

BSENSE

Apr 30

BSE+NSE Vol: 58.79 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Haleos Labs Limi

Medico Remedies

CCME Global

Amanta Healthcar

Jenburkt Pharma

Albert David

Kilitch Drugs

Valiant Laborato

Zim Laboratories

Solara Active PP

Influx Health.

Why is Zim Laboratories Ltd ?

Weak Long Term Fundamental Strength with a -4.97% CAGR growth in Operating Profits over the last 5 years

The company has been able to generate a Return on Equity (avg) of 6.55% signifying low profitability per unit of shareholders funds

The company has declared Negative results for the last 7 consecutive quarters

PAT(9M) At Rs 2.11 cr has Grown at -71.02%
ROCE(HY) Lowest at 6.21%
CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 1.45 cr

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zim Laboratories for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Zim Laboratories

0.02%

0.00

55.74%

Sensex

-4.15%

-0.31

13.42%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.54%

EBIT Growth (5y)

-4.97%

EBIT to Interest (avg)

3.16

Debt to EBITDA (avg)

2.09

Net Debt to Equity (avg)

0.48

Sales to Capital Employed (avg)

1.24

Tax Ratio

38.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.07%

ROCE (avg)

9.05%

ROE (avg)

6.55%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.85

EV to EBIT

33.97

EV to EBITDA

15.66

EV to Capital Employed

1.58

EV to Sales

1.55

PEG Ratio

Dividend Yield

ROCE (Latest)

4.35%

ROE (Latest)

2.62%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-10What is not working for the Company

PAT(9M)

At Rs 2.11 cr has Grown at -71.02%

ROCE(HY)

Lowest at 6.21%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 1.45 cr

DEBT-EQUITY RATIO(HY)

Highest at 0.48 times

Loading Valuation Snapshot...

Here's what is not working for Zim Laboratories

Profit After Tax (PAT) - Latest six months

At Rs 3.98 cr has Grown at -37.62%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is negative

PAT (Rs Cr)

Cash and Cash Equivalents - Half Yearly

Lowest at Rs 1.45 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio - Half Yearly

Highest at 0.48 times

in the last five half yearly periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio